2022

Thümmler, K. , Williams, M. T.S., Kitson, S., Sood, S., Akbar, M., Cole, J. J., Goodyear, C. S. , Hunter, E. and Soutar, R. (2022) Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis. OncoImmunology, 11(1), 2104070. (doi: 10.1080/2162402X.2022.2104070) (PMID:35936985) (PMCID:PMC9348127)

2021

Pujol-Navarro, N., Al Qaraghuli, M. M., Kubiak-Ossowska, K., Alsaadi, M. M., Horne, G. A. , Soutar, R. L., Paspali, E., Ferro, V. A., Williams, M. T.S. and Mulheran, P. A. (2021) Multiple myeloma: therapeutic delivery of antibodies and aptamers. Therapeutic Delivery, 12(10), pp. 705-722. (doi: 10.4155/tde-2021-0041) (PMID:34569269)

2020

Kemp, O., Horne, G. A. and Soutar, R. (2020) The psychological impact of COVID19 on a shielding high-risk cohort. Scottish Medical Journal, 65(4), pp. 120-122. (doi: 10.1177/0036933020951900) (PMID:32838668)

2015

Williams, M. T., Thümmler, K., Kitson, S., Soutar, R. and Goodyear, C. S. (2015) 3011 Fc Receptor Targeting Reduces Bone Disease in a Pre-Clinical Model of Multiple Myeloma. 57th ASH Annual Meeting and Exposition, Orange County, FL, USA, 4-8 Dec 2015.

Laing, A. A., Geddes, C. and Soutar, R. (2015) Renal impairment at presentation in multiple myeloma continues to be associated with poor survival. British Journal of Haematology, 169(6), pp. 901-902. (doi: 10.1111/bjh.13253) (PMID:25522297)

2014

Colombo, M. et al. (2014) Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget, 5(21), pp. 10393-10406. (doi: 10.18632/oncotarget.2084) (PMID:25257302) (PMCID:PMC4279381)

2011

Farrell, K., Stobo, D. and Soutar, R. (2011) Cervical amyloidoma successfully treated with Bortezomib and Dexamethasone. Journal of Clinical Oncology, 29(17), e512-e513. (doi: 10.1200/JCO.2011.34.6452)

D'Addio, A. et al. (2011) The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplantation, 46(3), pp. 356-363. (doi: 10.1038/bmt.2010.128)

2009

Doyle, A., Soutar, R. and Geddes, C. (2009) Multiple Myeloma in Chronic Kidney Disease. Nephron Clinical Practice, 111(1), C7-C11.

2008

Cutler, F., Niciu, C., Murphy, J. and Soutar, R. (2008) Use of TAGVHD warnings in patients receiving purine analogue chemotherapy. Transfusion Medicine, 18(2), pp. 137-138.

Laird, B., Whyte, G., Laird, J., Soutar, R., Welsh, J. and Fallon, M. (2008) An observational study of red cell transfusion in specialist palliative care. Palliative Medicine, 22(7), pp. 874-875.

2007

Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research, 13(17), pp. 5048-5055. (doi: 10.1158/1078-0432.CCR-07-0919)

2004

Soutar, R.L., Jobanputra, S. and Tait, R.C. (2004) A two-phase audit of fresh frozen plasma: a regional approach. Transfusion Medicine, 14(1), pp. 75-76. (doi: 10.1111/j.0958-7578.2004.00480.x) (PMID:15043596)

Articles

Thümmler, K. , Williams, M. T.S., Kitson, S., Sood, S., Akbar, M., Cole, J. J., Goodyear, C. S. , Hunter, E. and Soutar, R. (2022) Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis. OncoImmunology, 11(1), 2104070. (doi: 10.1080/2162402X.2022.2104070) (PMID:35936985) (PMCID:PMC9348127)

Pujol-Navarro, N., Al Qaraghuli, M. M., Kubiak-Ossowska, K., Alsaadi, M. M., Horne, G. A. , Soutar, R. L., Paspali, E., Ferro, V. A., Williams, M. T.S. and Mulheran, P. A. (2021) Multiple myeloma: therapeutic delivery of antibodies and aptamers. Therapeutic Delivery, 12(10), pp. 705-722. (doi: 10.4155/tde-2021-0041) (PMID:34569269)

Kemp, O., Horne, G. A. and Soutar, R. (2020) The psychological impact of COVID19 on a shielding high-risk cohort. Scottish Medical Journal, 65(4), pp. 120-122. (doi: 10.1177/0036933020951900) (PMID:32838668)

Laing, A. A., Geddes, C. and Soutar, R. (2015) Renal impairment at presentation in multiple myeloma continues to be associated with poor survival. British Journal of Haematology, 169(6), pp. 901-902. (doi: 10.1111/bjh.13253) (PMID:25522297)

Colombo, M. et al. (2014) Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget, 5(21), pp. 10393-10406. (doi: 10.18632/oncotarget.2084) (PMID:25257302) (PMCID:PMC4279381)

Farrell, K., Stobo, D. and Soutar, R. (2011) Cervical amyloidoma successfully treated with Bortezomib and Dexamethasone. Journal of Clinical Oncology, 29(17), e512-e513. (doi: 10.1200/JCO.2011.34.6452)

D'Addio, A. et al. (2011) The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplantation, 46(3), pp. 356-363. (doi: 10.1038/bmt.2010.128)

Doyle, A., Soutar, R. and Geddes, C. (2009) Multiple Myeloma in Chronic Kidney Disease. Nephron Clinical Practice, 111(1), C7-C11.

Cutler, F., Niciu, C., Murphy, J. and Soutar, R. (2008) Use of TAGVHD warnings in patients receiving purine analogue chemotherapy. Transfusion Medicine, 18(2), pp. 137-138.

Laird, B., Whyte, G., Laird, J., Soutar, R., Welsh, J. and Fallon, M. (2008) An observational study of red cell transfusion in specialist palliative care. Palliative Medicine, 22(7), pp. 874-875.

Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research, 13(17), pp. 5048-5055. (doi: 10.1158/1078-0432.CCR-07-0919)

Soutar, R.L., Jobanputra, S. and Tait, R.C. (2004) A two-phase audit of fresh frozen plasma: a regional approach. Transfusion Medicine, 14(1), pp. 75-76. (doi: 10.1111/j.0958-7578.2004.00480.x) (PMID:15043596)

Conference or Workshop Item

Williams, M. T., Thümmler, K., Kitson, S., Soutar, R. and Goodyear, C. S. (2015) 3011 Fc Receptor Targeting Reduces Bone Disease in a Pre-Clinical Model of Multiple Myeloma. 57th ASH Annual Meeting and Exposition, Orange County, FL, USA, 4-8 Dec 2015.